Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.

ABSTRACT:

Importance

Serotonin reuptake inhibitors (SRIs) are efficacious treatments for premenstrual dysphoric disorder (PMDD) when given daily or for half of the menstrual cycle during the luteal phase. Preliminary studies suggest that SRI treatment can be shortened to the interval from symptom onset through the beginning of menses.

Objective

To determine the efficacy of symptom-onset dosing with the SRI sertraline hydrochloride for treatment of PMDD.

Design, setting, and participants

A double-blind, placebo-controlled, multisite, parallel-group randomized clinical trial conducted September 1, 2007, to February 29, 2012, at 3 university medical centers. In all, 252 women with PMDD started treatment at symptom onset and continued until the first few days of menses for 6 menstr

SUBMITTER: Yonkers KA 

PROVIDER: S-EPMC4811029 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature